Table 2 Disease-modifying anti-rheumatic drugs (DMARDs) used during the 10 years of follow-up
DMARD | No (%) of patients | Mean time (months) ± SD |
|---|---|---|
Methotrexate | 86 (76.7%) | 63.0 ± 39.2 |
Sulfasalazine | 58 (51.7%) | 44.7 ± 42.6 |
Methotrexate + sulfasalazine | 33 (29.4%) | 37.7 ± 33.9 |
Gold salts | 33 (29.4%) | 23.2 ± 24.0 |
Hydroxychloroquine | 24 (21.4%) | 20.6 ± 17.5 |
Leflunomide | 24 (21.4%) | 20.7 ± 18.2 |
D-penicillamine | 2 (1.7%) | 23.4 ± 23.2 |
Ciclosporin | 4 (3.5%) | 23.0 ± 23.3 |
Etanercept | 12 (10.7%) | 16.7 ± 18.3 |
Infliximab | 9 (8.0%) | 19.4 ± 7.0 |
Adalimumab | 4 (3.5%) | 15.4 ± 18.7 |
Anakinra | 1 (0.8%) | 8.9 |
Abatacept | 1 (0.8%) | 2.1 |